Misoprostol Preferable to Ethacridine Lactate for Abortions at 13-20 Weeks of Pregnancy: Cuban Experience

Reproductive Health Matters

Volumn 16, Issue 31 SUPPL., 2008, Pages 189-195

  Velazco Boza, Alejandro ^a   Gómez Ponce de León, Rodolfo ^b   Salas Castillo, Luis ^c   Yi Mariño, Dania Rebeca ^c   Mitchell, Ellen MH ^d  

^a UNIVERSITY OF HAVANA   (Cuba)

^b IPAS   (United States)

^c Atención Integral a la Mujer Hospital Ginecoobstétrico América Arias   (Cuba)

^d NONE

Author keywords

Cuba; ethacridine lactate (Rivanol); misoprostol; second trimester abortion

Indexed keywords

ETHACRIDINE LACTATE; MISOPROSTOL; OXYTOCIN;

ABDOMINAL CRAMP; ADULT; ARTICLE; BLEEDING; CHILL; COHORT ANALYSIS; CONTROLLED STUDY; CURETTAGE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GESTATIONAL AGE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; NAUSEA AND VOMITING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND TRIMESTER ABORTION; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINAL HYSTERECTOMY;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADULT; CONFIDENCE INTERVALS; CUBA; ETHACRIDINE; FEMALE; HUMANS; MISOPROSTOL; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 50649105968     PISSN: 09688080     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-8080(08)31392-5     Document Type: Article

References (15)

1. Cabezas E. Salud reproductiva; aborto provocado. In: Rodríguez Armas O., Santiso Galvez R., and Calventi V. (Eds). Ginecologia Fertilidad Salud Reproductiva (1996), FLASOG, Caracas 691-724
2. Estadisticas de Salud de Cuba 1996-2002. Dirección Nacional de Estadística del Ministerio de Salud Pública de Cuba. At: <. www.dne.sld.cu/desplegables/indexcuba.htm >
3. Manual de Diagnóstico y Tratamiento en Obstetricia y Perinatología (1997), Ciencias Médicas, La Habana, Cuba 520
4. World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems (2003), WHO, Geneva 112
5. Ngai S.W., Tang O.S., and Ho P.C. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Practice & Research Clinical Obstetrics & Gynaecology 17 5 (2003) 765-775
6. Dodd J.M., and Crowther C.A. Misoprostol versus cervagem for the induction of termination of pregnancy in the second and third trimester: a systematic review. European Journal of Obstetrics & Gynaecology & Reproductive Biology 125 (2006) 3-8
7. Wong K.S., Ngai C.S.W., Wong A., et al. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy: a randomized trial. Contraception 58 (1998) 207-210
8. Velazco A., and Gomez Ponce de Leon R. Therapeutic abortion. In: Faúndes A. (Ed). Obstetric and Gynecological Uses of Misoprostol (2007), FLASOG 59-76
9. Guix C., Palacio M., Figueras F., et al. Efficacy of two regimens of misoprostol for early second-trimester pregnancy termination. Fetal Diagnosis and Therapy 20 (2005) 544-548
10. Li C., Wang W., Summer S., et al. Molecular mechanisms of antidiuretic effect of oxytocin. Journal of American Society of Nephrolology 18 (2007) 3067-3077
11. Alan Guttmacher Institute. Sharing responsibilities: women, society and abortion worldwide (1999), Alan Guttmacher Institute, New York
12. Benson J. Evaluating abortion-care programs: old challenges, new directions. Studies in Family Planning 36 (2005) 189-202
13. Rogo K. Improving technologies to reduce abortion-related mobidity and mortality. International Journal of Gynecology and Obstetrics 85 1 (2004) 73-82
14. Grimes D., Benson J., Singh S., et al. Unsafe abortion: the preventable pandemic. Lancet Sexual and Reproductive Health Series 268 (2006) 1908-1919
15. Ho P.C., Blumenthal P., Gemzell-Danielsson K., et al. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. International Journal of Gynecology & Obstetrics 99 (2007) 178-181